The new CEO has at least five years and a large M&A war chest to position Sanofi for life after the loss of exclusivity on ...

As Sanofi counts down the days before its new leader arrives, the French pharma’s interim CEO acknowledged there had been a ...

Sanofi’s multiple sclerosis medicine tolebrutinib was recommended for approval by European regulators, a boost for the ...

By Bhanvi Satija and Mariam Sunny LONDON, April 23 (Reuters) - French drugmaker Sanofi on Thursday reported first-quarter ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

Sanofi's new chief executive, Belén Garijo, will see her tenure at the company kick-started by a strong 2026 first quarter, ...

A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But ...

Sanofi India reported a 14% decline in Q1 net profit to ₹102.6 crore and a 4.9% drop in revenue to ₹472.3 crore. EBITDA fell ...

Sanofi (SNY) beats Q1 estimates as Dupixent sales jump and EPS rises; guidance reaffirmed amid CEO transition and pipeline ...

Sanofi has received approval from the US Food and Drug Administration (FDA) for a supplemental biologic licence application ...

After a series of regulatory and clinical setbacks for Sanofi’s tolebrutinib, the French pharma has scored a victory for the ...

Sanofi Consumer Healthcare India Ltd reported a 35.6% rise in Q1 net profit to ₹67.8 crore, driven by a 32.8% jump in revenue ...